All In Biotech

Drug Trial Radar · NCT06132113

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

DAREON™-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

65

Actual

Start

Jan 22, 2024

Primary completion

Oct 9, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has Part A1, Part A2, and Part B. Part A1 of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. Part A2 of this study is to find out how well people tolerate a low dose of BI 764532 combined with the chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC. Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it. Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour.

Conditions

  • Neuroendocrine Neoplasms

Interventions

  • BI 764532Drug

    BI 764532

  • CarboplatinDrug

    Standard of care

  • EtoposideDrug

    Standard of care

  • CisplatinDrug

    Standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A1: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: Up to 21 days.
  2. Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment periodTime frame: Up to 36 months.
  3. Part A2: Reduced monitoring: the occurrence of DLTs during the on-treatment periodTime frame: Up to 36 months.

Locations

21 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Hopital Louis Pradel

    Bron, France

  • INS Paoli-Calmettes

    Marseille, France

  • Klinikum der Universität München AÖR

    München, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Aichi Cancer Center Hospital

    Aichi, Nagoya, Japan

  • National Cancer Center Hospital East

    Chiba, Kashiwa, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Sahlgrenska Universitetsjukhuset

    Gothenburg, Sweden

  • Uppsala University Hospital

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.